CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s CEO, is scheduled to present at the UBS Global Life Sciences Conference at 10:00 a.m. ET on Thursday, September 20, 2012, at the Grand Hyatt, New York.
